Login to Your Account



Merck sees phase III CMV win with letermovir; details still to come

By Marie Powers
News Editor

Wednesday, October 19, 2016

Merck & Co. Inc. declared a phase III win with its antiviral, letermovir, to treat cytomegalovirus (CMV), reporting the therapy met the primary endpoint in the global, multicenter, randomized, placebo-controlled study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription